Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lonza Biologics
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Member News March 9, 2026 LONZA Biologics Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO™ (betibeglogene autotemcel), the only FDA-approved gene therapy for pediatric and adult patients with transfusion dependent beta-thalassemia Long-term collaboration began in 2013 and enabled commercial approval and rapid uptake for ZYNTEGLO™ in 2022 Basel, CH – Lonza, one of the world’s largest contract development and...
Lonza Expands its TheraPEAK® Product Portfolio with the Addition of AmpliCell® Cytokine Range and TheraPEAK® 293-GT® Medium
Member News October 6, 2025 LONZA Biologics AmpliCell® Cytokines enable cell expansion optimization, batch-to-batch consistency and easy transition from research to manufacturing TheraPEAK® 293-GT® Medium System aims to help accelerate development timelines and improve consistency from research through to GMP gene therapy production Switzerland, BS – Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced the launch of TheraPEAK® AmpliCell®...
Lonza Launches Next Generation 4D-Nucleofector® LV Unit PRO for Improved Electroporation in GMP Manufacturing
Member News July 7, 2025 LONZA Biologics Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing New system includes optimized cartridge design for improved performance for CRISPR-based knock-out, knock-in and transposition BASEL, CH – Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced the launch of 4D-Nucleofector® LV Unit PRO, their next-generation large-scale electroporation unit...
Maximizing The Value Of Early Phase Material Match Your Development And Manufacturing Path To Your IND Milestones
Raymond Donninger, Senior Director Commercial Development, Early Development Services, Lonza Biologics Reaching IND stage is a major milestone for biopharmaceutical companies.The drug development journey is long, expensive, resource straining, and risky due to high attrition rates.For example, not performing an optimal molecule de-risking and optimization program early in drug development can result in safety, efficacy, and/or manufacturability issues later in development, resulting in higher...
CHOK1SV GS‐KO® SSI Expression System: A combination of the Fer1L4 locus and glutamine synthetase selection
RESEARCH ARTICLE Marc Feary Corresponding Author marc.feary1@lonza.com orcid.org/0000-0001-7644-5290 R&D Cell Engineering, Lonza Biologics, Chesterford Research Park, UK Authors contributed equally to this publication Correspondence Marc Feary, Lonza Biologics, Cambridge, CB21 6GS, Mark A Moffat, Pfizer, Chesterfield, MO 63017, Email: marc.feary1@lonza.com or Email: mark.a.moffat@pfizer.com Contribution: Conceptualization, Data curation, Writing - original draft, Writing - review & editing...
Manufacturing Company Expands NH Facility, Adds 1,000 Jobs
Concord, NH — Governor Chris Sununu and State officials confirmed recently that Lonza Biologics, Inc. will be moving forward with the expansion of its Portsmouth facility, adding up to 1,000 jobs and up to one million square-feet of space. The company currently employs 800 at the facility where it primarily focuses on contract manufacturing. “We are thrilled that Lonza will be making a major additional investment in New Hampshire and adding more jobs to our local economy,” said Governor Sununu.
Lonza Biologics Expands Facility, Adding 1,000 Jobs
Governor Chris Sununu and State officials confirmed yesterday that Lonza Biologics, Inc. will be moving forward with the expansion of its Portsmouth facility, adding up to 1,000 jobs and up to one million square-feet of space. The company currently employs 800 at the facility where it primarily focuses on contract manufacturing. “We are thrilled that Lonza will be making a major additional investment in New Hampshire and adding more jobs to our local economy,” said Governor Sununu.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lonza
Contact Lonza, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack